Latham & Watkins Represents Zogenix, Inc. in US$200 Million Convertible Senior Notes Offering

Bicoastal deal team represented the global biopharmaceutical company in the offering.

September 28, 2020

Zogenix, Inc., a global biopharmaceutical company, has announced the pricing of its offering of US$200 million aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The issuance and sale of the notes are scheduled to settle on September 28, 2020, subject to customary closing conditions. Zogenix also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional US$30 million principal amount of notes.

Latham & Watkins LLP represented Zogenix in the offering with a capital markets team led by San Diego partners Cheston Larson and Matt Bush, with San Diego associates Anthony Gostanian, Jacob Steele, and Irene Fedoseienko. Advice was also provided on convertible debt matters by New York partner Greg Rodgers, with New York associates Andrew Blumenthal, Claire Solimine, and Jonathan Hernandez; and on tax matters by New York partners Bora Bozkurt and Elena Romanova, with New York associate Ron Moore.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.